Please use this identifier to cite or link to this item:
Title: Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma
Authors: Chow, P.K.H. 
MacHin, D.
Chen, Y.
Zhang, X.
Win, K.-M.
Hoang, H.-H.
Nguyen, B.-D.
Jin, M.-Y.
Lobo, R.
Findlay, M.
Lim, C.-H.
Tan, S.-B. 
Gandhi, M.
Soo, K.-C.
Keywords: advanced cancer
hepatocellular carcinoma
hormonal therapy
megestrol acetate
randomised controlled trial
Issue Date: 27-Sep-2011
Source: Chow, P.K.H., MacHin, D., Chen, Y., Zhang, X., Win, K.-M., Hoang, H.-H., Nguyen, B.-D., Jin, M.-Y., Lobo, R., Findlay, M., Lim, C.-H., Tan, S.-B., Gandhi, M., Soo, K.-C. (2011-09-27). Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. British Journal of Cancer 105 (7) : 945-952. ScholarBank@NUS Repository.
Abstract: Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. We tested megestrol acetate (MA) against placebo in the treatment of advanced HCC. Methods: From 2002 through 2007, this randomised double-blind trial enrolled 204 patients with treatment-naive advanced HCC (Eastern Cooperative Oncology Group (ECOG) performance rating of 0-3) from specialist care centres in six Asia-Pacific nations. Patients received placebo or MA (320 mg day -1). End points were overall survival (OS) and quality of life. Results: An adverse but not statistically significant difference in OS was found for MA vs placebo: median values 1.88 and 2.14 months, respectively (hazard ratio (HR)=1.25, 95% CI=0.92-1.71, P=0.16). However, OS was similar among patients of good functional status (Child-Pugh A and ECOG 0, 1 or 2) (44.3%) in both treatment groups, with the adverse effect of MA confined to those of poor status. Megestrol acetate patients had a worse global health status (not statistically significant) but reduced levels of appetite loss and nausea/vomiting. Conclusion: Megestrol acetate has no role in prolonging OS in advanced treatment-naive HCC. Overall survival with placebo differed markedly from that in similar trials conducted elsewhere, suggesting therapeutic outcomes may be strongly dependent on ECOG status and Child-Pugh score. © 2011 Cancer Research UK All rights reserved.
Source Title: British Journal of Cancer
ISSN: 00070920
DOI: 10.1038/bjc.2011.333
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Mar 8, 2018


checked on Feb 7, 2018

Page view(s)

checked on Mar 12, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.